Zahra, Eeman

e17594 Background: Cardiovascular disease (CVD) is the leading cause of death among women with ovarian cancer. This study investigates cardiovascular mortality in women with ovarian cancer across the United States, assessing trends by geography and urbanization. Methods: Mortality data from the CDC WONDER database (1999–2020) were analyzed. Females with ovarian cancer listed on the death certificate and cardiovascular disease as the cause of death were identified using ICD-10 codes. Age-adjusted mortality rates (per 100,000) were calculated and stratified by census region and urbanization. Trends were evaluated using Average Annual Percent Change (AAPC) calculated by the Joinpoint Regression Program V5.4.0. Results: From 1999 to 2018, cardiovascular mortality in ovarian cancer patients declined, with an APC of –2.09%, consistent across regions and urbanization levels. However, from 2018 to 2020, a concerning reversal occurred, with mortality increasing by +3.79% per year. The abrupt rise in mortality is observed in the Midwest region, with an APC of +3.99, and in small and medium metro regions, with APCs of +7.38 and +6.46, respectively. This reversal in cardiovascular mortality in ovarian cancer from 2018 to 2020 is likely due to the COVID-19 pandemic that disrupted screening and treatment. Conclusions: This 21-year analysis demonstrates a long-term decline in cardiovascular mortality among women with ovarian cancer, followed by a sharp reversal from 2018 to 2020. This increase suggests the urgent need for public health interventions to reduce cardiovascular risk among ovarian cancer patients.

e17524 Background: Cervical cancer remains one of the leading causes of female cancer mortality, while heart failure drives chronic disease burden. Their coexistence complicates outcomes through shared risk factors, cardiotoxicity, and mortality. This study examined cervical cancer mortality trends in patients with heart failure, assessed disparities, and aimed to inform integrated management strategies. Methods: We analyzed death certificates from CDC WONDER Database (1999–2020), using ICD-10 C53 (cervical cancer) and I50 (heart failure). Female mortality was stratified by race and urbanization. Joinpoint Regression Program V5.4.0 calculated Annual Percent Change (APC) and Average Annual Percent Change (AAPC). Results: A total of 5,534 deaths were identified. Age-adjusted mortality rates (AAMR) declined overall, but trends varied. Among females, mortality fell from 0.1102 per 100,000 in 1999 to 0.076 in 2020 (AAPC -1.28%). Three phases emerged: a modest decline (1999-2006, APC -1.45%), a rapid decline (2006-2009, APC -17.6%), and a concerning reversal (2009-2020, APC +3.27%). The latter increase may reflect reduced screening, declining vaccination rates, or COVID-19 disruptions.By urbanization, large central metropolitan areas showed a steady decline (APC -4.13%). By race, White women demonstrated a consistent reduction (APC -2.61%), indicating sustained benefits of screening and vaccination. Conclusions: Cervical cancer mortality in heart failure patients declined from 1999-2020, reflecting prevention and healthcare advances. However, disparities persist, with notable increases among women since 2009. These findings highlight successes but stress the urgent need for vaccination and screening.